Linoladiol

Estradiol Hemihydrate, the active ingredient in Linoladiol, is an estrogen presented as a vaginal formulation for vaginal use. It is used in hormone replacement therapy to alleviate estrogen‑deficiency symptoms in postmenopausal women.

GNH USA supplies Linoladiol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Estradiol Hemihydrate is employed in estrogen‑based hormone replacement therapy to address conditions related to low endogenous estrogen.

- Vaginal atrophy: improves dryness, irritation and dyspareunia. - Menopausal vasomotor symptoms: reduces frequency and severity of hot flashes and night sweats. - Hypoestrogenism due to ovarian failure: restores systemic estrogen activity and supports bone health.

Estradiol Hemihydrate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Vaginal irritation or discharge - Headache - Breast tenderness - Nausea or abdominal bloating - Mood changes - Mild skin rash

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Stroke or transient ischemic attack - Myocardial infarction - Endometrial hyperplasia or carcinoma - Severe allergic reaction (anaphylaxis) - Liver function abnormalities

When prescribing Estradiol Hemihydrate, clinicians should consider patient‑specific risk factors and monitor for adverse events.

- History of thromboembolism: avoid or use with caution. - Cardiovascular disease: assess risk before initiating therapy. - Liver impairment: adjust dosage or consider alternative therapy. - Undiagnosed vaginal bleeding: evaluate before use. - Pregnancy or breastfeeding: contraindicated unless benefits outweigh risks. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Estradiol Hemihydrate can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Aromatase inhibitors: antagonistic effect reducing estrogen activity. - Tamoxifen: competitive antagonism at estrogen receptors.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise estradiol plasma levels. - Antihypertensives: potential alteration of blood pressure control. - Lithium: may increase risk of breast tenderness and edema.